T/CACM 1118-2018 Active Group standards

T/CACM 1118-2018 Chinese medicine guide for prevention of chronic hepatitis B virus carriers

Publish Date: 2018-09-17 Implement Date: 2018-11-15 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Out of stock

Basic Information

Standard Code: T/CACM 1118-2018

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: Marine aquaculture and its products

ICS Name: Comprehensive Pharmaceutical Science

Publish Date: 2018-09-17

Implement Date: 2018-11-15

Scope

Main technical content: China is a high-incidence area for chronic hepatitis B virus (HBV) infection. According to the results of a national serological epidemiological survey of hepatitis B conducted in 2006, the HBsAg carrier rate among the general population aged 1 to 59 in China was 7.18%, and the HBsAg carrier rate among children under 5 was 0.96%. Based on this estimate, there are currently approximately 93 million chronic HBV carriers in China, including about 20 million chronic hepatitis B patients and 70 million chronic HBV carriers. In recent years, numerous studies, including liver biopsies, have shown that most HBV carriers have varying degrees of liver damage, which progresses to various types of hepatitis, liver cirrhosis, and even liver cancer over time. Foreign studies have found that 15% to 40% of chronic HBV carriers develop liver cirrhosis or liver cancer during the course of the disease. Therefore, it is particularly important to actively strengthen the attention and prevention and control of HBV carriers to control the transmission of the virus and the development and progression of the disease. At present, there are no effective intervention methods or treatment drugs for chronic HBV carriers in modern medicine, and antiviral treatment is generally not recommended. In recent years, traditional Chinese medicine (TCM) has achieved good therapeutic effects in treating HBV carriers. Multiple studies suggest that TCM can improve patients' quality of life, reduce HBsAg titers, inhibit HBV DNA replication, and alleviate liver inflammation. In the absence of clear antiviral indications and safe and effective intervention measures for Western medicine, TCM provides a new option for the prevention and treatment of this disease. Currently, there are no clinical practice guidelines for HBV carriers in China or abroad. Integrating and absorbing the research results and successful experiences of TCM interventions for HBV carriers at home and abroad, and draw